@article{2d3a8cfba3fd4ea394b667d033ab13c8,
title = "Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer",
abstract = "Introduction: As a result of the approval of several immune checkpoint inhibitors (ICIs) for the treatment of non-small cell lung cancer (NSCLC), many older adults are being treated with ICIs. Older adults are underrepresented in most pharmaceutical clinical trials. Therapy outcomes in this population with ICIs is particularly important since, age related factors may have an influence on the immune system. Methods: We utilized the MD Anderson Cancer Center Gemini Team's Lung Cancer Database to retrospectively study patients ≥70 years of age with advanced NSCLC treated with anti-PD-(L)1 monotherapy to look at the clinical outcomes. Results: 179 patients met the inclusion criteria for this retrospective analysis. There were 106 men and 73 women. The median age of the cohort was 74.9 years, and overall survival was 20.6 months. 27.6% of all patients had an objective response to therapy. In 33 patients who had radiological progression, treatment continued beyond progression due to clinical benefit. In this group, 6 patients had subsequent improvement in radiologic assessment. Age groups were not significantly associated with differences in clinical outcomes. Conclusions: This study suggests that anti-PD-(L)1 monotherapy is effective and well tolerated among older adults with advanced NSCLC. While pseudoprogression is rare, treatment beyond progression may provide clinical benefit in a subset of patients and warrants further investigation.",
keywords = "Elder adults, Immunotherapy, NSCLC, Treatment beyond progression",
author = "Mehmet Altan and Singhi, {Eric K.} and Michelle Worst and Carter, {Brett W.} and Leung, {Cheuk H.} and Lee, {J. Jack} and Presley, {Carolyn J.} and Jeff Lewis and Waree Rinsurongkawong and Vadeerat Rinsurongkawong and Jianjun Zhang and Gibbons, {Don L.} and Vaporciyan, {Ara A.} and Heymach, {John V.} and Mott, {Frank E.}",
note = "Funding Information: MA. reports receiving research funding (to institution) from Genentech, Nektar Therapeutics, Merck, GlaxoSmithKline, Novartis, Jounce Therapeutics, Bristol Myers Squibb, Eli Lilly, Adaptimmune, Shattuck Lab, and receives consultant and advisor fees from GlaxoSmithKline, Shattuck Lab and AstraZeneca outside of the submitted work. MW. Is an employee of Medscape, LLC, New York, NY, JZ? Reported receiving research funding and personal fees from Bristol-Myers Squibb, AstraZeneca, Geneplus, Roche and Innovent and grants from Merck and Johnson & Johnson outside of the current work. DLG serves on scientific advisory committees for AstraZeneca, GlaxoSmithKline, Sanofi, Lilly, Alethia Biotherapeutics and Janssen and has received research support from Janssen, Takeda, Ribon Therapeutics, Astellas, NGM Biopharmaceuticals and AstraZeneca outside of the submitted work. JVH. has served on the scientific advisory boards for AstraZeneca, Biotree, Bristol-Myers Squibb, Boehringer Ingelheim, Catalyst, EMD Serono, Genentech, GlaxoSmithKline, Guardant Health, Hengrui, Eli Lilly, Novartis, Seattle Genetics, Spectrum, Synta, Foundation Medicine, Takeda, Mirati Therapeutics, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, Pneuma Respiratory, Kairos Venture Investments, Roche,and Leads Biolabs. He receives research support from AstraZeneca, Bayer, GlaxoSmithKline, Spectrum, and Takeda, and royalties and licensing fees from Spectrum outside of the submitted work. The remaining authors declare no conflict of interest. Funding Information: Supported by the generous philanthropic contributions to The University of Texas MD Anderson Lung Moon Shot Program and the MD Anderson Cancer Center Support , Grant P30 CA01667 . CJP is supported by The National Institute of Aging , Grant R03 AG064374 . Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = may,
doi = "10.1016/j.cllc.2021.12.011",
language = "English (US)",
volume = "23",
pages = "236--243",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "3",
}